- Home
- NUTR vs AGEN Comparison
NUTR vs AGEN Comparison
Compare NUTR & AGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NUTR
- AGEN
- Stock Information
- Founded
- NUTR 2013
- AGEN 1994
- Country
- NUTR Indonesia
- AGEN United States
- Employees
- NUTR N/A
- AGEN N/A
- Industry
- NUTR
- AGEN Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- NUTR
- AGEN Health Care
- Exchange
- NUTR Nasdaq
- AGEN Nasdaq
- Market Cap
- NUTR 87.9M
- AGEN 87.7M
- IPO Year
- NUTR 2025
- AGEN 2000
- Fundamental
- Price
- NUTR $5.02
- AGEN $4.83
- Analyst Decision
- NUTR
- AGEN Buy
- Analyst Count
- NUTR 0
- AGEN 2
- Target Price
- NUTR N/A
- AGEN $14.50
- AVG Volume (30 Days)
- NUTR 1.3M
- AGEN 421.4K
- Earning Date
- NUTR 11-02-2025
- AGEN 08-11-2025
- Dividend Yield
- NUTR N/A
- AGEN N/A
- EPS Growth
- NUTR N/A
- AGEN N/A
- EPS
- NUTR 0.00
- AGEN N/A
- Revenue
- NUTR $1,743,679.00
- AGEN $101,706,000.00
- Revenue This Year
- NUTR N/A
- AGEN $26.25
- Revenue Next Year
- NUTR N/A
- AGEN N/A
- P/E Ratio
- NUTR $2,018.91
- AGEN N/A
- Revenue Growth
- NUTR N/A
- AGEN N/A
- 52 Week Low
- NUTR $3.40
- AGEN $1.38
- 52 Week High
- NUTR $5.17
- AGEN $7.34
- Technical
- Relative Strength Index (RSI)
- NUTR N/A
- AGEN 53.08
- Support Level
- NUTR N/A
- AGEN $4.12
- Resistance Level
- NUTR N/A
- AGEN $4.37
- Average True Range (ATR)
- NUTR 0.00
- AGEN 0.27
- MACD
- NUTR 0.00
- AGEN 0.09
- Stochastic Oscillator
- NUTR 0.00
- AGEN 66.36
About NUTR Nusatrip Incorporated Common Stock
NusaTrip Inc operates as an Online Travel Agent offering Hotel & Flight Tickets, Domestic and International. The Company currently operates in a single reportable operating segment with five different services: Ticketing, Online advertisement, Hotel reservation, Hotel technology platform software, and Ancillary. The group earns revenue through commissions, service fees, and advertising partnerships.
About AGEN Agenus Inc.
Agenus Inc is an American clinical-stage company with a pipeline of therapies designed to activate the body's immune system to fight cancer and infections, including immune-modulatory antibodies, adoptive cell therapies through its subsidiary MiNK Therapeutics Inc. and vaccine adjuvants through its subsidiary SaponiQx Inc. This robust product pipeline is supported by company's in-house capabilities, including current good manufacturing practice (cGMP) manufacturing and a clinical operations platform. The company's antibody candidates are botensilimab (a proprietary next-generation Fc-engineered CTLA-4 antibody, also known as AGEN1811) and balstilimab (a PD-1 antibody).